Open AccessAngiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
Author(s) -
Eric J. Velazquez,
David A. Morrow,
Adam D. DeVore,
Carol I. Duffy,
Andrew P. Ambrosy,
Kevin McCague,
Ricardo Rocha,
Eugene Braunwald
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1812851
Subject(s) - neprilysin , acute decompensated heart failure , heart failure , cardiology , medicine , chemistry , enzyme , biochemistry
Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of sacubitril-valsartan therapy is safe and effective among patients who are hospitalized for acute decompensated heart failure is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom